In a new post in our ongoing blog series with Health Affairs, ICER’s Sarah Emond discusses the challenge of achieving a “grand bargain” in which fair prices and fair access provide optimal benefits to both patients and the health system. At the root, she argues, is the different and sometimes-conflicting perspectives, objectives, and incentives of the many different stakeholders involved, including insurers, patients, the pharmaceutical industry, and others. She argues that real change will only be possible if disingenuous arguments are called out and all parties are willing to pursue open and honest efforts to collaborate; otherwise, large-scale policy changes may be needed that risk missing the best and fairest solution.
Read the full article here.
